Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes. Reply.
| Autor: | Gerstein HC; McMaster University, Hamilton, ON, Canada gerstein@mcmaster.ca., Khurmi NS; Sanofi, Bridgewater, NJ. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The New England journal of medicine [N Engl J Med] 2021 Nov 25; Vol. 385 (22), pp. 2107. |
| DOI: | 10.1056/NEJMc2115776 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|